Physician profile
Stephen Malamud
NPI 1265417323
$93,650.28
in general payments reported to CMS, 2019-2025
23 companies · $2,011 in 2025
The $2,011 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $27K · 2021: $23K · 2022: $1,437 · 2023: $3,866 · 2024: $1,413 · 2025: $2,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,790 · Long Term Medical Supply Or Device Loan: $1,530 · Food and Beverage: $902 · Education: $68.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,790.00 |
| Long Term Medical Supply Or Device Loan | $1,529.72 |
| Food and Beverage | $901.81 |
| Education | $68.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29,126.70 | 2019-2023 | Phesgo, Perjeta |
| Daiichi Sankyo INC. | $17,814.23 | 2020-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $16,942.74 | 2019-2024 | Enhertu, Lynparza, Imfinzi |
| Pfizer INC. | $13,384.08 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $11,226.23 | 2019-2025 | |
| Gilead Sciences, INC. | $3,571.17 | 2021-2024 | Trodelvy |
| Seagen INC. | $1,057.13 | 2021-2023 | Tukysa |
| Abbvie INC. | $86.50 | 2024 | |
| Lilly USA, LLC | $68.79 | 2025 | Verzenio |
| Tempus Ai, INC | $52.99 | 2024-2025 | Xt Cdx |
| Janssen Scientific Affairs, LLC | $46.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $41.92 | 2022 | |
| Incyte Corporation | $29.36 | 2025 | Monjuvi |
| Janssen Biotech, INC. | $28.56 | 2024 | Talvey, Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $26.95 | 2024 | Keytruda, Lynparza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $26.78 | 2023 | Epkinly |
| Mirati Therapeutics, INC. | $25.30 | 2023 | Krazati |
| Eisai INC. | $21.76 | 2022 | |
| Genmab U.S., INC. | $21.18 | 2023 | Tivdak |
| Stemline Therapeutics INC. | $19.50 | 2023 | Orserdu |
| Adaptive Biotechnologies Corporation | $17.30 | 2024 | Clonoseq |
| Array Biopharma INC | $14.52 | 2024 | Mektovi, Tukysa, Braftovi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Malamud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.